What is Artios Pharma?
Artios Pharma is a clinical-stage biotechnology company dedicated to pioneering novel approaches in the DNA damage response (DDR) field. By focusing on the fundamental pathways that cancer cells utilize to survive, Artios is developing a pipeline of differentiated medicines designed to improve outcomes for patients with hard-to-treat malignancies. The company's research and development efforts are centered on precision medicine, utilizing advanced biological insights to create targeted therapies that minimize off-target effects while maximizing therapeutic efficacy. With a team of seasoned DDR drug developers, Artios is effectively bridging the gap between academic innovation and commercial-scale pharmaceutical development.
How much funding has Artios Pharma raised?
Artios Pharma has raised a total of $385.2M across 4 funding rounds:
Series A
$33.2M
Series B
$84M
Series C
$153M
Series D
$115M
Series A (2016): $33.2M with participation from Merck Ventures, Arix Bioscience, AbbVie Ventures, Imperial Innovations Group plc, and SV Life Sciences
Series B (2018): $84M, investors not publicly disclosed
Series C (2021): $153M supported by Sofinnova Partners, Deep Track Capital, Omega Funds, TCG X, Piper Sandler, Invus, and Avidity Partners
Series D (2025): $115M, investors not publicly disclosed
Key Investors in Artios Pharma
Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability with a hands-on approach to company building.
Deep Track Capital
Deep Track Capital is an investment firm based in Greenwich, Connecticut, that focuses exclusively on the biotechnology and life sciences sectors.
Piper Sandler
Piper Sandler is a prominent investment bank and institutional securities firm providing comprehensive advisory and capital-raising services to the healthcare and life sciences industries.
What's next for Artios Pharma?
With the successful closure of this latest financing, Artios Pharma is well-positioned to advance its pre-clinical and clinical programs, including its innovative DDRi-ADC initiatives. The strategic focus will likely shift toward expanding clinical trial footprints and optimizing the pharmaceutical properties of its lead candidates. As the company matures, the integration of these novel DDR pathways into broader oncology treatment paradigms remains a primary objective. Investors and stakeholders will be monitoring the upcoming data readouts from the alnodesertib and ART6043 programs, which serve as critical milestones for the company's long-term value creation and potential for future strategic partnerships or market expansion.
See full Artios Pharma company page
